The 40% EPS miss signals deteriorating profitability despite revenue growth. Watch for analyst downgrades and potential cost-cutting measures. The reaffirmed guidance provides a floor, but the collaboration termination adds pipeline uncertainty. Monitor next quarter's margins and any updates on the R289 Phase 1b study.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 6 $26.67entry
- T+1 · 6mo ago 0.00%α +0.33% · $26.67
- T+5 · 6mo ago +10.12%α +8.99% · $29.37
- T+20 · 6mo ago +13.61%α +10.83% · $30.30
- T+60 · 4mo ago +38.02%α +35.96% · $36.81
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rigel Pharmaceuticals reported Q1 2026 GAAP diluted EPS of $0.44, missing consensus of $0.74 by 40.5%, despite 10% YoY revenue growth to $58.8M. Net income declined 24% YoY to $8.7M, and the company maintained its full-year revenue guidance of $275-290M. The miss was driven by higher R&D and SG&A costs, overshadowing strong product sales growth.
Key Financial Metrics
Key Facts
- Q1 2026 total revenues: $58.8M (up 10% YoY from $53.3M)
- Net product sales: $54.9M (up 26% YoY)
- GAAP diluted EPS: $0.44 vs consensus $0.74 (40.5% miss)
- Net income: $8.7M vs $11.4M in Q1 2025 (down 24%)
- 2026 revenue guidance reaffirmed at $275-290M
- Eli Lilly terminated collaboration on ocadusertib (effective June 15, 2026)
- Debt restructured: repaid $40M term loan, drew $8M on new $40M revolver
- Cash, cash equivalents and short-term investments: $146.7M as of March 31, 2026
Financial Impact
EPS miss of $0.30 vs consensus; net income decline of $2.8M YoY
Risk Factors
- Eli Lilly collaboration termination may impact future royalty streams
- Rising R&D and SG&A expenses pressuring margins
- High dependence on TAVALISSE sales (68% of product revenue)
- Potential need for additional capital if profitability continues to decline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001034842-26-000033 |
| Document: 0001034842-26-000033-index.html | 0001034842-26-000033 |
| Document: 0001034842-26-000033.txt | 0001034842-26-000033 |
| 8-K Data (Synthetic) | 0001034842-26-000033 |
Track record
12 reports on RIGL
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $45.03 Now $43.73 −2.89% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $44.21 Now $43.73 −1.09% settles Feb 12
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $43.91 Now $43.73 −0.41% settles Feb 8
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $39.65 Now $43.73 −10.29% settles Feb 4
- Aug 4, 202614w ago 8-K Mixed 6/10 Entry $40.48 to $50.92 Now $43.73 +8.03% ▲ +25.79% +25.60% vs SPY
- Jun 17, 202621w ago 8-K Neutral 4/10 Entry $32.91 to $45.35 Now $43.73 +32.88% ▲ +37.80% +35.91% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $32.08 to $48.67 Now $43.73 +36.32% ▲ +51.71% +47.32% vs SPY
- May 20, 202625w ago 8-K Neutral 2/10 Entry $29.19 to $42.45 Now $43.73 +49.81% ▲ +45.43% +41.13% vs SPY
- May 12, 202626w ago 8-K Bullish 7/10 Entry $32.13 to $40.17 Now $43.73 +36.10% ▲ +25.02% +20.59% vs SPY
- May 5, 202627w ago 8-K Bearish 7/10 Viewing Entry $26.67 to $36.81 Now $43.73 −63.97% ▼ −38.02% −35.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers